ArticleInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2022
Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer.
Article in International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Evolution of lymphovascular space invasion in early-stage endometrial carcinoma: stratification, quantification, and clinical implications: a systematic review.Archives of gynecology and obstetrics · 2025Pooled it
- Long-term outcomes in patients with endometrial cancer after sentinel lymph node biopsy versus lymphadenectomy alone: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.ESMO open · 2023Guideline
- Evaluation of prognostic significance of lymphovascular space invasion in early stage endometrial cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Working in concert: radiology, pathology, and gynecologic oncology applications of the 2023 FIGO updates in endometrial cancer staging.Abdominal radiology (New York) · 2026Review
- Association of immunohistochemically defined molecular subtypes with substantial lymphovascular space invasion in early-stage endometrial cancer: a single-center cohort of 575 patients.Journal of gynecologic oncology · 2026Article
- Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort.Journal of gynecologic oncology · 2026Article
- Comparative prognostic performance of International Federation of Gynecology and Obstetrics 2023 staging system and the 2025 European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology-European Society of Pathology risk classification in endometrial cancer.Obstetrics & gynecology science · 2026Article
- Decoding the 2023 FIGO Staging System in Endometrial Cancer: A Practical, Visually Guided Framework for Molecular Risk-Adapted Care Incorporating the 2025 Risk Group Update.Current oncology reports · 2026Review
- Prominent Lymphovascular Space Invasion as an Independent Prognostic Factor in LVSI-Positive Endometrioid Endometrial Carcinoma: Evidence for a Novel Three-Tiered Classification.Journal of clinical medicine · 2026Article
- Impact of the 2023 FIGO staging system on risk stratification in endometrial cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Radiomics nomogram from multiparametric magnetic resonance imaging for preoperative prediction of substantial lymphovascular space invasion in endometrial cancer.Abdominal radiology (New York) · 2026Article
- Preoperative Fibrinogen as a Biomarker Associated With Lymphovascular Space Invasion in Endometrial Carcinoma: A Cross-Sectional Study.Journal of family & reproductive health · 2026Article
- Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026Article
- Constructing a prediction model for lymph node metastasis in patients with incidental finding of endometrial cancer based on Fully-Connected Network.Journal of gynecologic oncology · 2026Article
- The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer.Journal of clinical medicine · 2025Article
- Article
- Bridging adjuvant treatment gaps: low and intermediate risk endometrial carcinoma patients care in Salah Azaiez Institute in Tunisia.The oncologist · 2025Article
- New histopathological and molecular findings in gynecological cancers.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- The past, present, and future of FIGO staging of endometrial cancer.Journal of gynecologic oncology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphovascular space invasion (LVSI) occurs in a minority of endometrial cancer (EC) cases, and the extent of LVSI is an important risk factor for recurrence and/or metastases. Our aim was to improve the reproducibility of measuring clinically meaningful LVSI by performing a quantitative analysis of the correlation between LVSI and the risk of pelvic lymph node recurrence in EC. EC samples from PORTEC-1 and PORTEC-2 trials were retrieved and used to collect quantitative data, including the number of LVSI-positive vessels per H&E-stained slide. Using a predefined threshold for clinical relevance, the risk of pelvic lymph node recurrence risk was calculated (Kaplan-Meier method, with Cox regression) using a stepwise adjustment for the number of LVSI-positive vessels. This analysis was then repeated in the Danish Gynecological Cancer Database (DGCD) cohort. Among patients in PORTEC-1 and PORTEC-2 trials who did not receive external beam radiotherapy, the 5-yr pelvic lymph node recurrence risk was 3.3%, 6.7% (P=0.51), and 26.3% (P<0.001), respectively when 0, 1 to 3, or ≥4 vessels had LVSI involvement; similar results were obtained for the DGCD cohort. Furthermore, both the average number of tumor cells in the largest embolus and the number of LVSI-positive H&E slides differed significantly between focal LVSI and substantial LVSI. On the basis of these results, we propose a numeric threshold (≥4 LVSI-involved vessels in at least one H&E slide) for defining clinically relevant LVSI in EC, thereby adding supportive data to the semiquantitative approach. This will help guide gynecologic pathologists to differentiate between focal and substantial LVSI, especially in borderline cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.